Skip to main content
Naomi Schlesinger

Naomi Schlesinger, MD

Languages spoken: English
  • Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Rheumatology)
  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Rheumatology
    Board Certification
    American Board of Internal Medicine (Sub: Rheumatology)

    Education history

    Fellowship Rheumatology - Medical College of Pennsylvania Fellow
    Internal Medicine - Jefferson Medical College of Thomas Jefferson University Resident
    Internship Internal Medicine - Medical College of Pennsylvania Intern
    Rotating - Technion - Israel Institute of Technology Intern
    Professional Medical Medicine - Technion - Israel Institute of Technology M.D.

    Selected Publications

    Journal Article

    1. Schlesinger N, Lipsky PE, Jablonski K, Jarjour W, Brunetti L, Young NA (2021). Components of tart cherry juice inhibit NFκB activation and inflammation in acute gout. Clin Exp Rheumatol, 40(7), 1293-1298.
    2. Schlesinger N, Sloan VS, Panush RS (2022). Numb From Rejection: Academic Publishing Is Not for the Faint-hearted. J Rheumatol, 49(5), 540-541.
    3. Brunetti L, Vekaria J, Lipsky PE, Schlesinger N (2021). Treatment of Acute Gout Flares in the Emergency Department: Prescribing Patterns and Revisit Rates. Ann Pharmacother, 56(4), 422-429.
    4. Schlesinger N, Rustgi VK, Yeo AE, Lipsky PE (2022). Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. Clin Exp Rheumatol.
    5. Hsu VM, Kozk E, Li Q, Bocskai M, Schlesinger N, Rosenthal A, McClure ST, Kovcs L, Blint L, Szamosi S, Szcs G, Carns M, Aren K, Goldberg I, Vradi A, Varga J (2021). Inorganic pyrophosphate is reduced in patients with systemic sclerosis. Rheumatology (Oxford), 61(3), 1158-1165.
    6. Schlesinger N, Elsaid MI, Rustgi VK (2022). The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study. Clin Exp Rheumatol, 40(3), 631-633.
    7. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R (2021). Colchicine for acute gout. Cochrane Database Syst Rev, 26(8).
    8. Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, Schlesinger N (2020). Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clin Rheumatol, 40(2), 683-692.
    9. Talaat M, Park K, Schlesinger N (2021). Contentious issues in gout management: the story so far. Open Access Rheumatol, 13, 111-22.
    10. Park K, Gupta NK, Olweny EO, Schlesinger N (2021). Beyond Arthritis: Understanding the Influence of Gout on Erectile Function: A Systematic Review. Urology, 153, 19-27.
    11. Kaveney A, Philipp CS, Prendergast NC, Kane I, Schlesinger N (2021). Muscular hematomas and COVID 19: A missed diagnosis? Annals of Short Reports and Clinical Images, 3(1), 1024.
    12. Jablonski K, Young NA, Henry C, Caution K, Kalyanasundaram A, Okafor I, Harb P, Schwarz E, Consiglio P, Cirimotich CM, Bratasz A, Sarkar A, Amer AO, Jarjour WN, Schlesinger N (2020). Physical activity prevents acute inflammation in a gout model by downregulation of TLR2 on circulating neutrophils as well as inhibition of serum CXCL1 and is associated with decreased pain and inflammation in gout patients. PLoS One, 15(10), e0237520.
    13. Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, Schlesinger N (2020). Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J Clin Med, 9(9).
    14. Huang YF, Yang KH, Chen SH, Xie Y, Huang CB, Qing YF, He DY, Wu LJ, Zhan F, Wang XQ, Zhou YQ, Kong QC, Wang K, Schlesinger N, Xu DT, Ma XJ, Gu JR (2020). [Practice guideline for patients with hyperuricemia/gout]. Zhonghua Nei Ke Za Zhi, 59(7), 519-527.
    15. Schlesinger N, Edwards NL, Yeo AE, Lipsky PE (2020). Development of a multivariable improvement measure for gout. Arthritis Res Ther, 22(1), 164.
    16. Edwards NL, Schlesinger N, Clark S, Arndt T, Lipsky PE (2020). Management of Gout in the United States: A Claims-based Analysis. ACR Open Rheumatol, 2(3), 180-187.
    17. Schlesinger N, Firestein BL, Brunetti L (2020). Colchicine in COVID-19: an Old Drug, New Use. Curr Pharmacol Rep, 6(4), 137-145.
    18. Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Scir C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Liot F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinamb HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vzquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrs M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klck V, Louthrenoo W, Dalbeth N (2019). Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis, 78(11), 1592-1600.
    19. Schlesinger N, Edwards NL, Khanna PP, Yeo AE, Lipsky PE (2019). Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. ACR Open Rheumatol, 1(4), 236-243.
    20. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrs M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Liot F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N (2017). Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res (Hoboken), 71(3), 427-434.
    21. Schlesinger N, Alikhan M, Doty RL (2019). Is the Sense of Smell Impaired in Gout Patients? Annals of Arthritis and Clinical Rheumatology, 2(1), 1008.
    22. Abdel Megid M, Borham A, Schlesinger N (2019). A case of dermatomyositis in a patient with Merkel Cell Carcinoma. Annals of Arthritis and Clinical Rheumatology, 2(1), 1009.
    23. Schlesinger N, Lu N, Choi HK (2018). Incident Gout and the Risk of Incident Erectile Dysfunction: A BMI-Matched Population-Based Study. J Rheumatol, 45(8), 1192-7.
    24. Pierre K, Schlesinger N, Androulakis IP (2017). The Hepato-Hypothalamic-Pituitary-Adrenal-Renal Axis: Mathematical Modeling of Cortisol's Production, Metabolism, and Seasonal Variation. J Biol Rhythms, 32(5), 469-484.
    25. Aqel SI, Hampton JM, Bruss M, Jones KT, Valiente GR, Wu LC, Young MC, Willis WL, Ardoin S, Agarwal S, Bolon B, Powell N, Sheridan J, Schlesinger N, Jarjour WN, Young NA (2017). Daily Moderate Exercise Is Beneficial and Social Stress Is Detrimental to Disease Pathology in Murine Lupus Nephritis. Front Physiol, 8, 236.
    26. Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD (2017). Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord, 18(1), 108.
    27. Hsu VM, Emge T, Schlesinger N (2016). X-ray diffraction analysis of spontaneously draining calcinosis in scleroderma patients. Scand J Rheumatol, 46(2), 118-121.
    28. Pierre K, Schlesinger N, Androulakis IP (2016). The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity. Physiol Genomics, 48(10), 719-738.
    29. Schlesinger N (2016). Reply: Lv ZT, Chen A. Vitamin D deficiency may explain the possible link between gout and erectile dysfunction. J Rheumatol, 43(8), 1617.
    30. Schlesinger N (2016). Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. Clinical Highlights for the Rheumatologist, 5(3), 38.
    31. de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scir CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N (2015). Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken), 68(5), 667-72.
    32. Schlesinger N, Etzel CJ, Greenberg J, Kremer J, Harrold LR (2016). Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. J Rheumatol, 43(5), 924-30.
    33. Schlesinger N, Radvanski DC, Cheng JQ, Kostis JB (2015). Erectile Dysfunction Is Common among Patients with Gout. J Rheumatol, 42(10), 1893-7.
    34. Pinals RS, Schlesinger N (2015). Did Michelangelo Have Gout? J Clin Rheumatol, 21(7), 364-7.
    35. Hsu V, Bramwit M, Schlesinger N (2015). Use of dual-energy computed tomography for the evaluation of calcinosis in patients with systemic sclerosis. Clin Rheumatol, 34(9), 1557-61.
    36. Vargas-Santos AB, Castelar-Pinheiro Gda R, Coutinho ES, Schumacher HR Jr, Singh JA, Schlesinger N (2015). Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS One, 10(8), e0135805.
    37. Schlesinger N, Radvanski DC, Young TC, McCoy JV, Eisenstein R, Moore DF (2015). Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department. Open Rheumatol J, 9, 21-6.
    38. Pai S, Raslan A, Schlesinger N (2015). Gout: Update on current therapeutics. Curr Treatm Opt Rheumatol, 1, 131-42.
    39. Schlesinger N (2015). Diagnosis of Gout: A Review to Aid the Clinician. Gout and Hyperuricemia, 2(4), 118-20.
    40. Pai S, Schlesinger N (2014). Some safety concerns when using drugs for acute and chronic gout. Drug Safety Quarterly, Summer(5), 1-4.
    41. Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, Alten R, March L, Strand V, Wells G, Khanna D, McQueen F, Schlesinger N, Boonen A, Boers M, Saag KG, Schumacher HR, Edwards NL (2013). OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol, 41(3), 569-73.
    42. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK (2012). Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis, 71(11), 1839-48.
    43. Schlesinger N, Rabinowitz R, Schlesinger M (2012). Pilot Studies of Cherry Juice Concentrate for Gout Flare Prophylaxis. J Arthritis, 1, 1.
    44. Schlesinger N, Maniatis G, Sharma R, Veysman BD (2012). The Diagnostic Eclipse. Hektoen Int, 4(2).
    45. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A (2011). Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis, 70(7), 1264-71.
    46. Schlesinger N, De Meulemeester M, Pikhlak A, Ycel AE, Richard D, Murphy V, Arulmani U, Sallstig P, So A (2011). Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther, 13(2), R53.
    47. Schlesinger N, Yasothan U, Kirkpatrick P (2011). Pegloticase. Nat Rev Drug Discov, 10(1), 17-8.
    48. Schlesinger N, Thiele RG (2010). The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis, 69(11), 1907-12.
    49. So A, De Meulemeester M, Pikhlak A, Ycel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N (2010). Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum, 62(10), 3064-76.
    50. Thiele RG, Schlesinger N (2009). Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int, 30(4), 495-503.
    51. Schlesinger N, Hassett AL, Neustadter L, Schumacher HR Jr (2010). Does acute synovitis (pseudogout) occur in patients with chronic pyrophosphate arthropathy (pseudo-osteoarthritis)? Clin Exp Rheumatol, 27(6), 940-4.
    52. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh J, Evans R, Waltrip RW, Diaz-Torne C, MacDonald P, McQueen F, Perez-Ruiz F (2009). Outcome domains for studies of acute and chronic gout. J Rheumatol, 36(10), 2342-5.
    53. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR (2009). Progress in measurement instruments for acute and chronic gout studies. J Rheumatol, 36(10), 2346-55.
    54. Schlesinger N, Norquist JM, Watson DJ (2009). Serum urate during acute gout. J Rheumatol, 36(6), 1287-9.
    55. Kimel AF, Schlesinger N (2009). Polymyalgia Rheumatica: to unmask the real culprit. J Clin Outcomes Manag, 16(3), 137-45.
    56. Edwards NL, Schlesinger N (2009). Gout: scale of the disease. Clin Geriatr, 9(Suppl 4).
    57. Schlesinger N (2009). Management of gout in seniors: addressing barriers and setting goals for optimal control. Clin Geriatr, 9(Suppl 4), 8-14.
    58. Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG (2007). A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis, 67(6), 888-91.
    59. Perez-Ruiz F, Dalbeth N, Schlesinger N (2008). Febuxostat, a novel drug for the treatment of hyperuricemia and gout. Future Medicine, 3(5), 421-7.
    60. Thiele RG, Schlesinger N (2007). Diagnosis of gout by ultrasound. Rheumatology (Oxford), 46(7), 1116-21.
    61. Petersel D, Schlesinger N (2007). Treatment of acute gout in hospitalized patients. J Rheumatol, 34(7), 1566-8.
    62. Schlesinger N (2006). Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol, 12(6), 275-6.
    63. Schlesinger N, Moore DF, Sun JD, Schumacher HR Jr (2006). A survey of current evaluation and treatment of gout. J Rheumatol, 33(10), 2050-2.
    64. Schlesinger N (2006). Reply: Seasonal variation of primary neuropsychiatric SLE. J Rheumatol, 33(9), 1914.
    65. Schlesinger N (2006). What next when gout remains afoot? Consultant, 46, 144.
    66. Schlesinger N, Schlesinger M, Seshan SV (2005). Seasonal variation of lupus nephritis: high prevalence of class V lupus nephritis during the winter and spring. J Rheumatol, 32(6), 1053-7.
    67. Schlesinger N, Lardizabal A, Rao J, Rao J, McDonald R (2005). Tuberculosis of the spine: experience in an inner city hospital. J Clin Rheumatol, 11(1), 17-20.
    68. Schlesinger N, Schlesinger M (2010). Seasonal variation of rheumatic diseases. Discov Med, 5(25), 64-9.
    69. Schlesinger N (2004). Clues to pathogenesis of fibromyalgia in patients with sickle cell disease. J Rheumatol, 31(3), 598-600.
    70. Schlesinger N, Katz M, Ingber A (2002). Nail involvement in pemphigus vulgaris. Br J Dermatol, 146(5), 836-9.
    71. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, Hoffman BI, Schumacher HR Jr (2002). Local ice therapy during bouts of acute gouty arthritis. J Rheumatol, 29(2), 331-4.
    72. Schlesinger N, Neustadter L, Schumacher HR (2008). Lytic Bone Lesions as a Prominent Feature in Waldenstrom's Macroglobulinemia. J Clin Rheumatol, 6(3), 150-3.
    73. Schlesinger N, Baker DG, Schumacher HR Jr (2000). Gout: How well have diagnostic tests and therapies been evaluated? Curr Opin Orthop, 11, 71-6.
    74. Schlesinger N, Gowin KM, Baker DG, Beutler AM, Hoffman BI, Schumacher HR Jr (1998). Acute gouty arthritis is seasonal. J Rheumatol, 25(2), 342-4.
    75. Schlesinger N, Hoffman BI (2008). Fungal Bursitis: Olecranon Bursitis Caused by Candida parapsilosis with Review of the Literature. J Clin Rheumatol, 1(4), 232-5.

    Review

    1. Schlesinger N, Brunetti L, Androulakis IP (2022). Does seasonality of the microbiota contribute to the seasonality of acute gout flare? [Review]. Clin Exp Rheumatol.
    2. Ramessar N, Borad A, Schlesinger N (2022). The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review. [Review]. Lupus, 31(3), 287-296.
    3. Schlesinger N, Padnick-Silver L, LaMoreaux B (2022). Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. [Review]. BioDrugs, 36(2), 95-103.
    4. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R (2021). Colchicine for acute gout. [Review]. Cochrane Database Syst Rev, 8, CD006190.
    5. Park K, Gupta NK, Olweny EO, Schlesinger N (2020). Beyond Arthritis: Understanding the Influence of Gout on Erectile Function: A Systematic Review. [Review]. Urology, 153, 19-27.
    6. Talaat M, Park K, Schlesinger N (2021). Contentious Issues in Gout Management: The Story so Far. [Review]. Open Access Rheumatol, 13, 111-122.
    7. Carcione J, Bodofsky S, LaMoreaux B, Schlesinger N (2020). Beyond Medical Treatment: Surgical Treatment of Gout. [Review]. Curr Rheumatol Rep, 23(1), 1.
    8. Bodofsky S, Merriman TR, Thomas TJ, Schlesinger N (2020). Advances in our understanding of gout as an auto-inflammatory disease. [Review]. Semin Arthritis Rheum, 50(5), 1089-1100.
    9. Schlesinger N, Brunetti L (2019). Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol. [Review]. Semin Arthritis Rheum, 50(3), 444-450.
    10. Schlesinger N, Lipsky PE (2020). Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. [Review]. Semin Arthritis Rheum, 50(3S), S31-S38.
    11. Hsu V, Varga J, Schlesinger N (2019). Calcinosis in scleroderma made crystal clear. [Review]. Curr Opin Rheumatol, 31(6), 589-594.
    12. Scherholz ML, Schlesinger N, Androulakis IP (2019). Chronopharmacology of glucocorticoids. [Review]. Adv Drug Deliv Rev, 151-152, 245-261.
    13. Schlesinger N (2017). The safety of treatment options available for gout. [Review]. Expert Opin Drug Saf, 16(4), 429-436.
    14. Keenan RT, Schlesinger N (2016). New and Pipeline Drugs for Gout. [Review]. Curr Rheumatol Rep, 18(6), 32.
    15. Sharon Y, Schlesinger N (2016). Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. [Review]. Curr Rheumatol Rep, 18(6), 37.
    16. Rao RT, Pierre KK, Schlesinger N, Androulakis IP (2017). The Potential of Circadian Realignment in Rheumatoid Arthritis. [Review]. Crit Rev Biomed Eng, 44(3), 177-191.
    17. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landew RB (2014). Non-steroidal anti-inflammatory drugs for acute gout. [Review]. Cochrane Database Syst Rev, (9), CD010120.
    18. van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D (2014). Colchicine for acute gout. [Review]. Cochrane Database Syst Rev, (8), CD006190.
    19. Schlesinger N (2014). Treatment of acute gout. [Review]. Rheum Dis Clin North Am, 40(2), 329-41.
    20. Schlesinger N (2014). Anti-interleukin-1 therapy in the management of gout. [Review]. Curr Rheumatol Rep, 16(2), 398.
    21. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R (2013). Intra-articular glucocorticoids for acute gout. [Review]. Cochrane Database Syst Rev, (4), CD009920.
    22. Schlesinger N (2012). Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. [Review]. Semin Arthritis Rheum, 42(2), 155-65.
    23. Schlesinger N (2012). Canakinumab in gout. [Review]. Expert Opin Biol Ther, 12(9), 1265-75.
    24. Schlesinger N (2011). Difficult-to-treat gouty arthritis: a disease warranting better management. [Review]. Drugs, 71(11), 1413-39.
    25. Schlesinger N (2010). New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. [Review]. Curr Rheumatol Rep, 12(2), 130-4.
    26. Schlesinger N, Dalbeth N, Perez-Ruiz F (2009). Gout--what are the treatment options? [Review]. Expert Opin Pharmacother, 10(8), 1319-28.
    27. Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N (2009). Imaging of gout: findings and utility. [Review]. Arthritis Res Ther, 11(3), 232.
    28. Schlesinger I, Schlesinger N (2008). Uric acid in Parkinson's disease. [Review]. Mov Disord, 23(12), 1653-7.
    29. Ebert EC, Hagspiel KD, Nagar M, Schlesinger N (2008). Gastrointestinal involvement in polyarteritis nodosa. [Review]. Clin Gastroenterol Hepatol, 6(9), 960-6.
    30. Perez-Ruiz F, Schlesinger N (2008). Management of gout. [Review]. Scand J Rheumatol, 37(2), 81-9.
    31. Schlesinger N (2008). Overview of the management of acute gout and the role of adrenocorticotropic hormone. [Review]. Drugs, 68(4), 407-15.
    32. Schlesinger N (2008). Diagnosis of gout. [Review]. Minerva Med, 98(6), 759-67.
    33. Schlesinger N (2007). Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. [Review]. Expert Opin Drug Saf, 6(6), 625-9.
    34. Schlesinger N, Schumacher R, Catton M, Maxwell L (2006). Colchicine for acute gout. [Review]. Cochrane Database Syst Rev, (4), CD006190.
    35. Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H, OMERACT 7 Special Interest Group (2005). Outcome measures for acute and chronic gout. [Review]. J Rheumatol, 32(12), 2452-5.
    36. Schlesinger N (2005). Diagnosis of gout: clinical, laboratory, and radiologic findings. [Review]. Am J Manag Care, 11(15 Suppl), S443-50; quiz S465-8.
    37. Schlesinger N (2005). Dietary factors and hyperuricaemia. [Review]. Curr Pharm Des, 11(32), 4133-8.
    38. Schlesinger N (2004). Management of acute and chronic gouty arthritis: present state-of-the-art. [Review]. Drugs, 64(21), 2399-416.
    39. Schlesinger N, Schumacher HR Jr (2002). Update on gout. [Review]. Arthritis Rheum, 47(5), 563-5.
    40. Schlesinger N, Schumacher HR Jr (2001). Gout: can management be improved? [Review]. Curr Opin Rheumatol, 13(3), 240-4.
    41. Schlesinger N, Baker DG, Schumacher HR Jr (1999). How well have diagnostic tests and therapies for gout been evaluated? [Review]. Curr Opin Rheumatol, 11(5), 441-5.

    Book

    1. Schlesinger N, Lipsky P (2018). Gout (1st Edition). Elsevier.
    2. Dalbeth N, Perez-Ruiz F, Schlesinger N (2012). Gout. Future Science Group E-Book Series.

    Book Chapter

    1. Schlesinger N (2022). Clinical Features of Gout. In Stone JH (Ed.), A Clinician’s Pearls and Myths in Rheumatology (Second Edition). Springer.
    2. Schlesinger N (2022). Gout Treatment. In Stone JH (Ed.), A Clinician’s Pearls and Myths in Rheumatology (Second Edition). Springer.
    3. Schlesinger N (2022). Chapter 160: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (7th Edition). Elsevier.
    4. Schlesinger N (2022). Section Crystal-Related Arthropathies, Chapter 194: Clinical Features of Gout. In Silman AJ, Hochberg MC, Smolen JS, Weinblatt ME, Weisman MH (Eds.), Rheumatology, 2-Volume Set (8th Edition). Elsevier.
    5. Schlesinger N (2020). Chapter 158: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (6th Edition). Elsevier.
    6. Schlesinger N, Kay JC (2019). Chapter 34: Gouty Inflammation. In Hashkes P, Laxer R, Simon A (Eds.), Textbook of Autoinflammation (1st Edition, pp. 635-45). Springer.
    7. Schlesinger N, Lipsky PE (2018). Preface. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
    8. Schlesinger N (2018). Chapter 13: Nonpharmacologic treatment of gout. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
    9. Schlesinger N (2018). Chapter 15: Current Pharmacological Treatments of Chronic Gout. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
    10. Schlesinger N (2018). Current Pharmacological Treatments of Chronic Gout. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
    11. Schlesinger N (2018). Epilogue. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
    12. Schlesinger N (2018). Section 17. Crystal-Related Arthropathies Rheumatology, Chapter 191: Clinical Features of Gout. In Silman AJ, Hochberg MC, Smolen JS, Weinblatt ME, Weisman MH (Eds.), Rheumatology, 2-Volume Set (7th Edition). Elsevier.
    13. Schlesinger N (2017). Chapter 176: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (5th Edition, pp. 928-32). Elsevier.
    14. Keenan R, Pai S, Schlesinger N (2016). Chapter 43: Imaging of gout. In Doherty M, Arden N, Hunter D, Bijlsma H, Dalbeth N (Eds.), Oxford Textbook of Osteoarthritis and Crystal Arthropathy (Oxford Textbooks in Rheumatology) (3rd Edition). Oxford University Press.
    15. Dalbeth N, Perez-Ruiz F, Schlesinger N (2013). Gout. In Dalbeth N, Perez-Ruiz F, Schlesinger N (Eds.), Future Science Group (FSG) E-Book Series (pp. 2-5).
    16. Schlesinger N (2013). Chapter 5: Clinical Features of Gout. In Dalbeth N, Perez-Ruiz F, Schlesinger N (Eds.), Future Science Group (FSG) E-Book Series (pp. 70-7).
    17. Schlesinger N (2013). Chapter 16: Therapies for Acute Flares and Gout Flare Prophylaxis. In Dalbeth N, Perez-Ruiz F, Schlesinger N (Eds.), E-book Series: Gout (pp. 202-211). Future Science Group.
    18. Schlesinger N (2012). Chapter 175: Gout. In Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (4th Edition, pp. 916-20). Elsevier.
    19. Schlesinger N (2012). Chapter 10: Treatment of Acute Gout. In Terkeltaub R (Ed.), Gout and Crystal-Induced Arthropathies (1st Edition, pp. 121-30). Elsevier.
    20. Schlesinger N (2008). Chapter 10: Hyperuricemia, Gout and Diet. In Coleman LA (Ed.), Nutrition and Rheumatic Disease (pp. 169-82). Humana Press, Inc.
    21. Schlesinger N (2007). Chapter 187: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (3rd Edition, pp. 952-7). Elsevier Publishers.
    22. Schlesinger N, Schumacher HR (2003). Gout: How much of what we do is evidence based? In Tugwell P, Shea B (Eds.), Evidence-based Rheumatology (pp. 65-95). London: British Medical Journal Books.
    23. Schlesinger N (2001). Osteoarthritis: pathology, epidemiology and risk factors. In Stitik TP (Ed.), Osteoarthritis [Physical Medicine and Rehabilitation: State of the Art Reviews] (15: 1, pp. 1-9). Philadelphia: Hanley and Belfus Publishers.
    24. Schlesinger N (1999). Connective tissue disorders. In Singleton JK, Sandowski SA, Green-Hernandez C, Hovath TV, DiGregorio RV, Holzemer SP (Eds.), Primary Care (pp. 32-452). Lippincott-Raven.

    Conference Proceedings

    1. Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL (2007). Outcome evaluations in gout. J Rheumatol, Canada, 34(6), 1381-5.

    Commentary

    1. Schlesinger N (2016). Crystal arthritis: New recommendations highlight the need for more research. Nat Rev Rheumatol, 12(11), 628-630.
    2. Dalbeth N, Perez-Ruiz F, Edwards NL, Schlesinger N (2008). In defense of research into the crystal induced arthropathies. J Rheumatol, 35(11), 2278-9; author reply 2279.
    3. Schlesinger I, Schlesinger N (2008). Re: Gout and risk of Parkinson disease: a prospective study. Neurology, 71(1), 70; author reply 70.
    4. Schlesinger N (2008). Febuxostat : a viewpoint by Naomi Schlesinger. Drugs, 68(13), 1875-6.
    5. Schlesinger N (2004). Purine-rich foods and the risk of gout in men. N Engl J Med, 350(24), 2520-1; author reply 2520-1.
    6. Schlesinger N, Schumacher HR Jr, Beutler AM (1998). Serum uric acid in acute gout. Ann Rheum Dis, 57(7), 443-4.
    7. Schlesinger N (1997). Identification of Gulf War syndrome: methodological issues and medical illnesses. JAMA, 278(5), 383; author reply 385-7.
    8. Schlesinger N, Huppert A, Hoch S (1995). Cyclosporine and methotrexate for severe rheumatoid arthritis. N Engl J Med, 333(23), 1567; author reply 1568-9.

    Case Report

    1. Sedhom D, Herrmann A, DSouza M, Fyfe B, Zaldana F, Schlesinger N, Rustgi V (2018). Vanishing Bile Duct Syndrome in a Patient with Uterine Cancer and Paraneoplastic Systemic Sclerosis. ACG Case Rep J, 5, e95.
    2. Bieber A, Schlesinger N, Fawaz A, Mader R (2017). Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature. Semin Arthritis Rheum, 47(6), 843-848.
    3. Hsu V, Bramwit M, Schlesinger N (2015). Dual-energy computed tomography for the evaluation of calcinosis in systemic sclerosis. J Rheumatol, 42(2), 345-6.
    4. Chehab MR, Goyal J, Schlesinger N (2012). Tophaceous pustule-like rash in a patient with gout. J Rheumatol, 39(1), 194-5.
    5. Schlesinger N (2010). Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med, 122(2), 157-61.
    6. Lam A, Toma W, Schlesinger N (2006). Mycobacterium marinum arthritis mimicking rheumatoid arthritis. J Rheumatol, 33(4), 817-9.

    Editorial

    1. Schlesinger N (2011). Can ultrasonography make identification of asymptomatic hyperuricemic individuals at risk for developing gouty arthritis more crystal clear? Arthritis Res Ther, 13(2), 107.
    2. Schlesinger N (2011). The role of ultrasonography in imaging of gouty arthritis. 3(6), 609-11.

    Letter

    1. Schlesinger N, Brunetti L (2020). Treatment of Acute Gout Flares in the Emergency Department: Comment on the Article by Dalal et al. [Letter to the editor]. Arthritis Care Res (Hoboken), 72(11), 1663.
    2. Lipsky PE, Edwards NL, Fields TR, Keenan RT, Mandell BF, Schlesinger N (2020). Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al. [Letter to the editor]. Arthritis Care Res (Hoboken), 72(10), 1506-1507.
    3. Schlesinger N (2019). Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels. [Letter to the editor]. Ann Intern Med, 170(10), 737-738.
    4. Schlesinger N, Schlesinger M (2013). Previously reported prior studies of cherry juice concentrate for gout flare prophylaxis: comment on the article by Zhang et al. [Letter to the editor]. Arthritis Rheum, 65(4), 1135-6.
    5. Schlesinger N (2005). Acute gouty arthritis is seasonal: possible clues to understanding the pathogenesis of gouty arthritis. [Letter to the editor]. J Clin Rheumatol, 11(4), 240-2.
    6. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr (2001). Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. [Letter to the editor]. Clin Exp Rheumatol, 19(5), 595.
    7. Schlesinger N, Kapila R (2000). Tendinitis during the course of an acute hepatitis B virus infection [Letter to the editor]. J Clin Rheumatol, 6(2), 10.
    8. Schlesinger N, Baker DG, Schumacher HR Jr (1998). Serum urate during bouts of acute gouty arthritis. [Letter to the editor]. J Rheumatol, 24(11), 2265-6.
    9. Schlesinger N, Baker DG, Schumacher HR Jr (1997). Persian Gulf War myalgia syndrome. [Letter to the editor]. J Rheumatol, 24(5), 1018-9.

    Abstract

    1. Brunetti L, Wang L, Wassef A, Brinker A, Buckley B, Lipsky P, Kong A, Schlesinger N (2021). Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients [Abstract]. 73(10 Suppl).
    2. Schlesinger N, Sumpter N, Dalbeth N, Stamp L, Merriman T (2021). Is There a Difference in Self-reported Flare Frequency Between Men and Women? [Abstract]. 73(10 Suppl).
    3. Schlesinger N, Edwards N, Clark S, Lipsky P (2020). Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout [Abstract]. 79(Suppl 1), 1873.
    4. Schlesinger N, Yeo A, Lipsky P (2020). Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase [Abstract]. 79(Suppl 1), 450.
    5. Brunetti L, Vekaria J, Lipsky P, Schlesinger N (2020). Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares. Poster presentation at the Asia-Pacific League of Associations For Rheumatology Congress, Kyoto, Japan [Abstract]. 79(Suppl 1), 442.
    6. Sherman Y, Lipsky P, Bramwit M, Schlesinger N (2020). Dual-Energy Computed Tomography in Gout Patients: Is it Useful in General Practice? [Abstract]. 79(Suppl 1), 1763.
    7. Schlesinger N, Jablonski K, Schwarz E, Young N (2020). Physical Activity Decreases Pain and Inflammation in Gout Patients. Poster presentation at the Asia-Pacific League of Associations for Rheumatology, Kyoto, Japan [Abstract]. 79(Suppl 1), 1762.
    8. Brunetti L, Vekaria J, Lipsky P, Schlesinger N (2020). Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares [Abstract]. 72(10 Suppl).
    9. Brunetti L, Diawara O, Tsai A, Firestein B, Nahass R, Poiani G, Schlesinger N (2020). Colchicine to Weather the Storm in Hospitalized Patients with COVID-19 [Abstract]. 72(10 Suppl).
    10. Schlesinger N, Edwards NL, Yeo A, Lipsky P (2019). Development of a Multivariable Improvement Measure for Gout. Oral presentation [Abstract]. 78(Suppl 2).
    11. Schlesinger N, Elsaid MI, Rustgi VK (2019). The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A population Based Study [Abstract]. 78(Suppl 2).
    12. Schlesinger N, Alikhan M, Doty R (2019). Is the Sense of Smell Impaired in Gout Patients? [Abstract]. 78(Suppl 2).
    13. Edwards L, Schlesinger N, Clark S, Arndt T, Lipsky P (2019). Management of Advanced Gout: a Claims-Based Analysis from the United States [Abstract]. 78(Suppl 2).
    14. Sidor M, Zuckerman R, Schlesinger N, Sussman R, Sabahath H, Hsu V (2019). Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease. Poster presentation at the 6th Systemic Sclerosis World Congress (virtual) [Abstract]. 71(10 Suppl).
    15. Hsu V, Schlesinger N, Li Q, Varga J (2019). Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders. Poster presentation at the 6th Systemic Sclerosis World Congress (virtual) [Abstract]. 71(10 Suppl).
    16. Edwards N, Schlesinger N, Clark S, Paige J, Arndt T, Lipsky P (2019). Gout Management in the Medical Community: A Claims-Based Analysis [Abstract]. 71(10 Suppl).
    17. Schlesinger N, Edwards N, Clark S, Lipsky P (2019). Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout [Abstract]. 71(10 Suppl).
    18. Schlesinger N, Edwards N, Yeo A, Lipsky P (2019). Development of a Multivariable Improvement Measure for Gout [Abstract]. 71(10 Suppl).
    19. Schlesinger N, Yeo A, Lipsky P (2019). Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase [Abstract]. 71(10 Suppl).
    20. Schlesinger N, Jablonski K, Harb P, Henry C, Schwarz E, Okafor I, Jarjour W, Young N (2019). Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels [Abstract]. 71(10 Suppl).
    21. Jablonski K, Sandoval B, Harb P, Kalyanasundaram A, Hampton JM, Jarjour WN, Schlesinger N, Young NA (2018). Moderate physical activity downregulates TLR2 expression on circulating neutrophils and leads to reduced IL-1β locally in an acute mouse model of gout. Oral presentation at the EULAR, Annual European Congress of Rheumatology, Amsterdam, Netherlands [Abstract]. 77(Suppl), 204.
    22. Young NA, Jablonski K, Sandoval B, Kalyanasundaram A, Harb P, Hampton JM, Jarjour WN, Schlesinger N (2018). Daily exercise suppresses acute pro-inflammatory cytokine expression systemically and IL-1β locally in a murine model of gout [Abstract]. 77(Suppl), 1235.
    23. Aamar S, Kerpel A, Rabinowitz R, Levy P, Zelig O, Schlesinger N, Schlesinger M (2018). Cell surface antigens and Intracytoplasmic cytokines in CD20 bright and low lymphocyte subpopulations in rheumatoid arthritis patients. Oral presentation at the EULAR, Annual European Congress of Rheumatology, Amsterdam, Netherlands [Abstract]. 77(Suppl), 268.
    24. Elsaid MI, Rustgi VK, Schlesinger N (2018). The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A population Based Study [Abstract]. 70(10 Suppl).
    25. Mandell BF, Schlesinger N, Edwards NL, Yeo A, Lipsky P (2018). Influence of renal function on the velocity of tophus resolution and achievement of disease remission in patients with chronic refractory gout treated with pegloticase [Abstract]. 70(10 Suppl).
    26. Jablonski K, Young NA, Sandoval B, Harb P, Scharwz E Henry C, Kalyanasundaram A, Okafor I, Jarjour WN, Schlesinger N (2018). Physical Activity at Lower Intensities Reduces Localized IL-1b in Murine Model of Gout by Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression [Abstract]. 70(10 Suppl).
    27. Young NA, Jablonski K, Sandoval B, Harb P, Scharwz E Henry C, Arbaji H, Okafor I, Jarjour WN, Schlesinger N (2018). Oral Cherry Juice Concentrate Inhibits Localized NFκB activity and Histopathological Infiltrates in a Murine Model of Acute Gout [Abstract]. 70(10 Suppl).
    28. Schlesinger N, Khanna P, Yeo A, Lipsky PE (2017). Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout. Poster presentation at the EULAR, Annual European Congress of Rheumatology, Madrid, Spain [Abstract]. 69(10 Suppl).
    29. Li X, Wei Q, Schlesinger N, Gu (2017). Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout [Abstract]. 69(10 Suppl).
    30. Young NA, Jablonski K, Sharma J, Thomas E, Snoad B, Hampton J, Jarjour W, Schlesinger N (2017). Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy [Abstract]. 69(10 Suppl).
    31. Alten R, Bardin T, Schumacher HR, Bloch M, Lheritier K, Machein U, Junge G, So A, Schlesinger N (2015). Safety and Efficacy of Canakinumab in Frequently Flaring Gouty Arthritis Patients who are Contraindicated, Intolerant or Unresponsive to Non-Steroidal Antiinflammatory drugs and/or Colchicine: Results from 3 years follow-up [Abstract]. 74(Suppl 2), 544.
    32. Vargas dos Santos AB, da Rocha Castelar Pinheiro G, Freire Coutinho ES, Schlesinger N (2015). A Survey Of Gout Treatment By Brazilian Rheumatologists Evaluated According To The 2012 ACR Guidelines [Abstract]. 74(Suppl 2), 1206.
    33. Biernat-Kaluza E, Schlesinger N (2015). Lemon juice reduces serum uric acid level via alkalization of urine in gouty and hyperuremic patients-a pilot study [Abstract]. 74(Suppl 2), 774.
    34. Schlesinger N, Bardin T, Bloch M, Lheritier K, Machein U, Junge G, So A, Alten R (2015). 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-inflammatory Drugs and/or Colchicine [Abstract]. 67(10 Suppl), 2344.
    35. Hsu VM, Emge T, Schlesinger N (2015). X-ray diffraction of spontaneously draining calcinosis in patients with scleroderma [Abstract]. 67(10 Suppl), 2969.
    36. Schlesinger N, Etzel C, Greenberg J, Kremer J, Harrold L (2014). Gout flare prophylaxis evaluated according to the 2012 American College of Rheumatology (ACR) guidelines: analysis from the CORRONA Gout Registry. Poster presented at the 4th Eastern Forum of Gout, Beijing, China [Abstract]. 73(Suppl 2), 782.
    37. Hsu VM, Bramwit M, Schlesinger N (2014). Dual Energy Computed Tomography for the evaluation of calcinosis in systemic sclerosis [Abstract]. 73(Suppl 2), 571.
    38. Alten R, Schlesinger N, So A, Schumacher HRBloch M, Machein U, Richard D, Lheritier K, Bardin T (2014). Long-term safety and efficacy of canakinumab vs. triamcinolone acetonide in patients with frequent acute gouty arthritis attacks who are contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine [Abstract]. 73(Suppl 2), 785.
    39. Harrold LR, Etzel C, Gibofsky A, Kremer J, Pillinger M, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg J (2014). Sex differences in gout characteristics: tailoring care for women and men. Oral Presentation at the EULAR, Annual European Congress of Rheumatology, Paris, France [Abstract]. 73(Suppl 2), 112.
    40. Schlesinger N, Radvanski D, Kostis JB (2014). Erectile dysfunction in gout patients. Oral presentation at the EULAR, Annual European Congress of Rheumatology, Paris, France [Abstract]. 73(Suppl 2), 111-2.
    41. Schlesinger N, Radvanski D, Kostis JB (2014). All Men with Gout Should Be Screened For Erectile Dysfunction [Abstract]. 66(10 Suppl), S160.
    42. Hsu VM, Bramwit M, Schlesinger N (2014). Dual Energy Computed Tomography for the evaluation of calcinosis in systemic sclerosis [Abstract]. 66(10 Suppl), S159.
    43. Schlesinger N, Alten R, Schumacher HR, Bloch M, Lheritier K, Richard D, Bardin T, Stancati A, So A (2014). Canakinumab in Frequent Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to NSAIDs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up [Abstract]. 66(10 Suppl), S1686.
    44. Schlesinger N, Radvanski D, Young TC, Eisenstein R, Moore DF (2013). Diagnosis and treatment of acute gouty arthritis at a university hospital Emergency Department [Abstract]. 72(Suppl 3), 381.
    45. Schlesinger N, Radvanski D, Tomanovich P (2013). Association of gouty arthritis severity with patients’ mental and physical health-related quality of life, work productivity and medical resource utilization [Abstract]. 72(Suppl 3), 353.
    46. Harrold LR, Etzel C, Greenberg J, Pillinger M, Saag K, Schlesinger N, Terkeltaub R, Cox V, Kremer J (2013). Sex Differences in Gout Evaluation and Management [Abstract]. 65(10 Suppl), S506.
    47. Schlesinger N, Young TC, Radvanski D, Moore DF, Eisenstein R (2013). Treatment of acute gout in the emergency department evaluated according to the 2012 American College of Rheumatology guidelines. Poster presented at the American College of Rheumatology/Association of Reproductive Health Professionals Annual Scientific Meeting, San Diego, CA [Abstract]. 65(10 Suppl), S848.
    48. Sunkureddi P, Schlesinger N, Kiechle T, Shpilsky A, So A (2012). Effect of serum urate level on prevention of flare in acute gouty arthritis patients with canakinumab [Abstract]. 71(Suppl 3), 699.
    49. Sunkureddi P, Bardin T, Alten R, Schlesinger N, Bloch M, T Kiechle T, Krammer G, Shpilsky A, So A (2012). Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3 [Abstract]. 71(Suppl 3), 447.
    50. Schlesinger N, Dundeva-Baleva P, Abdel-Megid A, Borham A (2012). Trochanteric Bursitis: Is there Ultrasonographic Evidence to Suggest Inflammation? [Abstract]. 71(Suppl 3), 275.
    51. Schlesinger N, Sunkureddi P, Alten R, Bardin T, Shpilsky A, Kiechle T, So A (2012). The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis [Abstract]. 71(Suppl 3), 699.
    52. Schlesinger N, Alten R, Bardin T, Bloch M, Shpilsky A, Krammer G, Kiechle T, So A (2012). Effect of canakinumab vs triamcinolone acetonide for treatment of gouty arthritis in patients who are unable to use NSAIDs and colchicine or with severe gouty arthritis. Poster tour EULAR, Annual European Congress of Rheumatology, Madrid, Spain [Abstract]. 71(Suppl 3), 439.
    53. So A, Bardin T, Bloch M, Shpilsky A, Kiechle T, Schlesinger N (2012). Early response to treatment is a surrogate marker of flare recurrence in acute gouty arthritis [Abstract]. 71(Suppl 3), 441.
    54. Bardin T, Alten R, Schlesinger N, Shpilsky A, Kiechle T, So A (2012). Tophi spread, acute joints and flare frequency predict reflare in gouty arthritis: a spatio-temporal mode [Abstract]. 71(Suppl 3), 450.
    55. Alten R, Bloch M, Bardin T, So A, Shpilsky A, Nebesky JM, Kiechle, Schlesinger N (2012). Efficacy and safety of canakinumab vs triamcinolone acetonide in persistent or elderly gouty arthritis patients [Abstract]. 71(Suppl 3), 700.
    56. So A, Alten R, Schumacher HR, Bloch M, Bardin T, John MR, Krammer G, Nebesky JM, Tao A, Schlesinger N (2012). Long-term safety and efficacy of canakinumab in patients with gouty arthritis [Abstract]. 64(10 Suppl), S144.
    57. Bardin T, So A, Alten R, Bloch M, John MR, Krammer G, Nebesky JM, Tao A, Schlesinger N (2012). Efficacy and Safety of Canakinumab vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Non-steroidal Anti-Inflammatory Drugs and Colchicine, and on Stable ULT or Unable to Use ULT [Abstract]. 64(10 Suppl), S1911.
    58. Schlesinger N, Lin Liao HY, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2011). Canakinumab Provides Superior Prophylaxis Against Acute Gouty Arthritis Flares During Initiation of Allopurinol Therapy: Results of a Double-Blind, Randomised Study. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, San Fransisco, CA [Abstract]. 127(Suppl 2), AB227.
    59. Schlesinger N, Lin Liao HY, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2011). Canakinumab Relieves Symptoms of Acute Flares and Improves Health-Related Quality Of Life (HRQoL) in Difficult-To-Treat Gouty Arthritis Patients by Suppressing Inflammation: Results of a Randomized, Dose-Ranging Study. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, San Fransisco, CA [Abstract]. 127(Suppl 2), AB227.
    60. So A, De Meulemeester M, Pikhlak A, Ycel AE, Bodalia B, Kerrane J, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2011). Canakinumab (ACZ885) relieves pain and controls inflammation rapidly in patients with difficult-to-treat gouty arthritis: comparison with triamcinolone acetonide. Oral presentation at the British Society for Rheumatology Annual Conference [Abstract]. 50(Suppl 3), iii31-4.
    61. So A, De Meulemeester M, Pikhlak A, Ycel AE, Bodalia B, Kerrane J, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2011). Rapid improvement in health-related quality of life (HRQoL) in gouty arthritis patients treated with canakinumab (ACZ885) compared to triamcinolone acetonide. Oral presentation at the British Society for Rheumatology Annual Conference [Abstract]. 50(Suppl 3), iii85-6.
    62. Schlesinger N, Lin H-Y, De Meulemeester M, Nasonov EL, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2011). Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Poster presentation at the British Society for Rheumatology [Abstract]. 50(Suppl 3), iii85-6.
    63. So A, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, Murphy A, Richard D, Schlesinger N (2011). Canakinumab versus triamcinolone acetonide in the treatment of acute flares in gouty arthritis in patients contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine [Abstract]. 70(Suppl 3), 686.
    64. So A, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, Murphy A, Richard D, Schlesinger N (2011). Canakinumab effectively reduces markers of inflammation in difficult to treat acute gouty arthritis: results from two controlled trials comparing canakinumab with triamcinolone acetonide [Abstract]. 70(Suppl 3), 686.
    65. Schlesinger N, Alten R, Schumacher HR, Bardin T, Bloch M, Shpilsky A, Gimona A, Kiechle T, Krammer G, So A (2011). Long-term safety and efficacy of canakinumab (ACZ885) in the prevention of flares in gouty arthritis patients [Abstract]. 70(Suppl 3), 181.
    66. Schlesinger N, Alten R, Schumacher HR, Bardin T, Bloch M, Shpilsky A, Gimona A, Kiechle T, Krammer G, So A (2011). Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: results of the β-relieved ii study (response in acute flare and in prevention of episodes of re-flare in gout). Oral presentation at the EULAR, Annual European Congress of Rheumatology, London, England, United Kingdom [Abstract]. 70(Suppl 3), 186.
    67. Schlesinger N, Alten R, Schumacher HR, Bardin T, Bloch M, Shpilsky A, Gimona A, Kiechle T, Krammer G, So A (2011). Efficacy of canakinumab vs triamcinolone acetonide in preventing recurrent flares in acute gouty arthritis patients contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine: results from two pivotal studies [Abstract]. 70(Suppl 3), 103.
    68. So A, Alten R, Bardin T, Bloch M, Schumacher HR, Rolfe A, Murphy V, Sallstig P, Richard D, Gimona A Schlesinger N (2011). A controlled trial of canakinumab vs triamcinolone acetonide in acute gouty arthritis patients: results of the β-relieved study (response in acute flare and in prevention of episodes of re-flare in gout) [Abstract]. 70(Suppl 3), 104.
    69. Bardin T, Schlesinger N, Alten R, Bloch M, Schumacher HR, Gimona A, Krammer G, Tao A, Stricker K, So A (2011). Surrogate markers of comorbidities: impact of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients [Abstract]. 70(Suppl 3), 182.
    70. Bardin T, Schlesinger N, Alten R, Bloch M, Schumacher HR, Gimona A, Krammer G, Tao A, Stricker K, So A (2011). Baseline epidemiology characteristics of comorbidities in gouty arthritis patients frequently flaring: results from two pivotal studies [Abstract]. 70(Suppl 3), 697.
    71. Dundeva-Baleva P, Abdel-Megid A, Borham A, Schlesinger N (2011). Trochanteric Bursitis: Is there Ultrasonographic Evidence to Suggest Inflammation? [Abstract]. 63(10 Suppl), S1898.
    72. Sunkureddi P, Bardin T, Alten R, Schlesinger N, Bloch M, Kiechle T, Krammer G, Shpilsky A, So A (2011). Effect of IL-1β Inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5 [Abstract]. 63(10 Suppl), S1020.
    73. So A, Alten R, Schumacher HR, Bardin T, Bloch M, Richard D, Karpov A, Kiechle T, Schlesinger N (2011). Inflammation Suppression over 24 Weeks in Patients with Gouty Arthritis: Results from two Phase-III Core and Extension Studies Comparing Canakinumab with Triamcinolone Acetonide [Abstract]. 63(10 Suppl), S1019.
    74. Brown JP, So A, Dikranian A, Alten R, Bardin T, Schumacher HR, Gimona A, Krammer G, Karpov A, Schlesinger N (2011). Long-term efficacy and safety of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients [Abstract]. 63(10 Suppl), S1016.
    75. Alten R, So A, Kivitz A, Bardin T, Bloch M, Gimona A, Widmer A, Krammer G, Schlesinger N, Schumacher HR (2011). Efficacy of Canakinumab vs Triamcinolone Acetonide Re-Treatment in Gouty Arthritis Patients with Limited Treatment Options: 24- Week Results from β-RELIEVED and β-RELIEVED-II Studies [Abstract]. 63(10 Suppl), S1029.
    76. Schlesinger N, Brown JP, Bardin T, Kiechle T, Shpilsky A, Alten R, So A (2011). Comparison of Pain Intensity, Incidence of New Flares, Safety and Tolerability of Canakinumab vs Triamcinolone Acetonide in Gouty Arthritis Patients with Cardiovascular Diseases or with Cardiovascular Risk Factors [Abstract]. 63(10 Suppl), S1028.
    77. Schlesinger N, De Meulemeester M, Shamim T, Pikhlak A, Ycel AE, Arulmani U, Richard D, Murphy V, Sallstig P, So A (2010). Canakinumab vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in “difficult to treat” gouty arthritis [Abstract]. 16(Suppl 3), S65.
    78. Schlesinger N, De Meulemeester M, Shamim T, Pikhlak A, Yucel AE, Arulmani U, Richard D, Murphy V, Sallstig P, So A (2010). Canakinumab vs. Triamcinolone Acetonide for Treatment of “difficult to treat” gouty arthritis patients. Oral presentation at the 30th World Congress of Internal Medicine, Melbourne, Australia [Abstract]. 40(Suppl 1), 49.
    79. Mricke R, So A, De Meulemeester M, Shamim T, Pikhlak A, Ycel E, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. Triamcinolone acetonide in der Behandlung von Gichtpatienten – refraktär oder kontraindiziert zur Behandlung mit NSARs und/oder Colchizin – bei akuten arthritischen Schüben und zur Prävention von wieder auftretenden Gichtattacken. Poster presented at the 117th Congress of the German Society of Internal Medicine [Abstract]. 105(Suppl 1), 88.
    80. So A, D Meulemeester M, Bodalia B, Shamim T, Pikhlak A, Ycel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to NSAIDS and/or colchicine. Poster presented at the British Society of Rheumatology [Abstract]. 49(1), i60-1.
    81. Schlesinger N, De Meulemeester M, Shamim T, Pikhlak A, Arulmani U, Richard D, Murphy V, Sallstig P, So A (2010). Canakinumab vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in “difficult to treat” gouty arthritis. Poster presented at the Pan-American League of Associations for Rheumatology Congress [Abstract]. 16(3), S23.
    82. So A, De Meulemeester M, Pikhlak A, Ycel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Efficacy of canakinumab (ACZ885) compared to triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients. Poster presented at SGR http://www.smw.ch/fileadmin/smw/pdf/Supplementa_2010/smw_Suppl-182.pdf [Abstract]. 140(Suppl 182).
    83. Schlesinger N (2010). Prophylaxis with cherries should be considered in the treatment of gout [Abstract]. 69(Suppl 3), 380.
    84. Schlesinger N, Rabinowitz R, Schlesinger M (2010). Effect of cherry juice concentrate on the secretion of interleukins by human monocytes exposed to monosodium urate crystals in vitro [Abstract]. 69(Suppl 3), 379.
    85. Thiele R, Schlesinger N (2010). Ultrasound detects more erosions and tophi in gout than conventional radiography [Abstract]. 69(Suppl 3), 385.
    86. So A, De Meulemeester M, Pikhlak A, Ycel AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2010). Effect of canakinumab (ACZ885) and triamcinolone acetonide on the Health-Related Quality of Life (HRQoL) measures in patients with gouty arthritis [Abstract]. 69(Suppl 3), 383.
    87. So A, De Meulemeester M, Pikhlak A, Ycel AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients [Abstract]. 69(Suppl 3), 291.
    88. Schlesinger N, Lin Liao HY, Whittington D, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Murphy V, Richard D, Sallstig P, So A (2010). Efficacy of canakinumab (ACZ885) in the prevention of flares in gout patients initiating allopurinol therapy. Oral Presentation at the European League Against Rheumatism Congress, Rome, Italy [Abstract]. 69(Suppl 3), S121.
    89. Thiele RG, Schlesinger N (2010). Ultrasound Detects More Erosions in Gout Than Conventional Radiography [Abstract]. 62(10 Suppl), S889.
    90. So A, De Meulemeester M, Pikhlak A, Ycel AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2010). Rapid improvement in health-related quality of life (HRQoL) in gouty arthritis patients treated with canakinumab (ACZ885) compared to triamcinolone acetonide. Oral Presentation at the American College of Rheumatology & Association of Rheumatology Health Professionals Annual Scientific Meeting, Atlanta, GA [Abstract]. 62(10 Suppl), S1423.
    91. So A, De Meulemeester M, Pikhlak A, Ycel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) relieves Pain and Controls Inflammation rapidly In Patients with Difficult-To-Treat Gouty Arthritis: Comparison with Triamcinolone Acetonide [Abstract]. 62(10 Suppl), S145.
    92. Schlesinger N, Lin Liao HY, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2010). Efficacy of canakinumab (ACZ885), a fully human anti-Interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Oral Presentation at the ACR Plenary Session I, Discovery 2010, American College of Rheumatology/Association of Reproductive Health Professionals Annual Scientific Meeting, Atlanta, GA [Abstract]. 62(10 Suppl), S2087.
    93. So A, Lin H-Y, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. colchicine in the prevention of flares in gout patients initiating allopurinol therapy. Oral presentation at the Asia-Pacific League of Associations for Rheumatology, Hong Kong [Abstract]. 13(Suppl 1), 176.
    94. So A, Lin H-Y, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. colchicine in the prevention of flares in gouty arthritis patients initiating allopurinol therapy. Oral presentation at SGR 2010 [Abstract]. 140(Suppl 182).
    95. Schlesinger N, Kudipudi R, Kapila R (2009). Not everything that is infectious tenosynovitis is caused by neisseria gonorrhea [Abstract]. 68(Suppl 3), S58.
    96. Schlesinger N, Savage SV, Das KM, Hassett AL (2009). The prevalence and role of fibromyalgia in inflammatory bowel disease [Abstract]. 68(Suppl 3), S692.
    97. Hassett AL, Savage SV, Dihmes SE, Buyske S, Schlesinger N (2009). Positive affect as a resilience factor in fibromyalgia and other complex symptom disorders [Abstract]. 59(9 Suppl), S1142.
    98. Thiele RG, Schlesinger N (2009). Ultrasonography shows active inflammation in clinically unaffected joints in chronic tophaceous gout [Abstract]. 59(9 Suppl), S1512.
    99. So A, De Meulemeester M, Shamim T, Pikhlak A, Ycel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2009). Canakinumab (ACZ885) vs. triamcinolone actonide for treatment of acute gout in patients refractory or contraindicated to NSAIDs and/or colchicine. Late breaking abstract [Abstract]. 60(LB4), 3660-1.
    100. Hassett AL, Radvanski DC, Savage SV, Schlesinger N, Sigal LH (2008). Exploring the role of somatosensory amplification in fibromyalgia: pain, fatigue and functioning [Abstract]. 67(Suppl 11), 254.
    101. Hassett AL, Radvanski DC, Sigal LH, Buyske S, Schlesinger N, Lehrer PM (2008). Preliminary Results from a Randomized Controlled Trial of Heart Rate Variability Biofeedback in Fibromyalgia [Abstract]. 67(Suppl 11), 638.
    102. Schlesinger N, JM Norquist, J Boice, DJ Watson (2008). Serum Urate During Acute Gouty Arthritis Attacks [Abstract]. 67(Suppl 11), 247.
    103. Schlesinger N, Hassett AL, Bard S, Savage SV, Das KM (2008). The prevalence and role of fibromyalgia in inflammatory bowel disease: preliminary findings [Abstract]. 67(Suppl 11), 639.
    104. Norquist JM, Levine K, Schlesinger N, Boice J, Watson DJ (2008). Critical Evaluation of Recommended Outcome Assessments in Acute Gouty Arthritis [Abstract]. 67(Suppl 11), 247.
    105. Thiele RG, Anandarajah AP, Tabechian D, Schlesinger N (2008). Comparing the use of ultrasonography, magnetic resonance imaging, conventional radiography high-resolution CT scanning and 3-dimensional rendering in patients with crystal proven gout [Abstract]. 67(Suppl 11), 248.
    106. Schlesinger N, Norquist JM, Boice J, Watson DJ (2008). Serum Urate Levels During Acute Gout [Abstract]. 58(9 Suppl), S26.
    107. Thiele RG, Anandarajah AP, Tabechian D, Schlesinger N (2008). Comparing the use of ultrasonography, magnetic resonance imaging, conventional radiography high-resolution CT scanning and 3-dimensional rendering in patients with crystal proven gout [Abstract]. 58(9 Suppl), S805.
    108. Hassett AL, Radvanski DC, Sigal LH, Buyske S, Schlesinger N, Lehrer PM (2008). Preliminary Results from a Randomized Controlled Trial of Heart Rate Variability Biofeedback in Fibromyalgia [Abstract]. 58(9 Suppl), S1179.
    109. Schlesinger N, Norquist JM, Holmes R, Boice J, Watson DJ (2007). Validation of a patient- reported assessment of pain in acute gouty arthritis [Abstract]. S0352.
    110. Schlesinger N, Ron Y, Chen CC (2007). Do cherries reduce acute gouty attacks in patients with gouty arthritis? [Abstract]. S0742.
    111. Thiele R, Schlesinger N (2007). Ultrasonography shows disappearance of urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved [Abstract]. S0746.
    112. Borham A, Taha R, Griffin F, Schlesinger N (2007). Post -call residents manifest a fibromyalgia-like syndrome [Abstract]. 56(9 Suppl), S113.
    113. Thiele R, Schlesinger N (2007). Ultrasound detects calcium pyrophosphate dehydrate crystal deposition in hyaline cartilage more readily than conventional radiography and MRI in pyrophosphate arthropathy [Abstract]. 56(9 Suppl), S1618.
    114. Harrison J, Faiz A, Schlesinger N (2007). Disturbed sleep in adult patients with sickle cell disease assessed by the Pittsburgh sleep quality index [Abstract]. 110(11), S.
    115. Thiele R, Schlesinger N (2005). Ultrasonography is a reliable, non-invasive method for diagnosing gout [Abstract]. 52(9 Suppl), S809.
    116. Petersel D, ONeill K, Schlesinger N (2005). Treatment of acute gout in hospitalized patients [Abstract]. 52(9 Suppl), S199.
    117. Borham A, El-Garf AK, Abd El-Monem, Mahmoud G, Fouad H, Schlesinger N (2005). Familial Mediterranean Fever (FMF) among Egyptians [Abstract]. 52(9 Suppl), S590.
    118. Schlesinger N, Schlesinger M, Seshan SV (2003). Seasonal Variations of Lupus Nephritis [Abstract]. 48(9 Suppl), S1496.
    119. Schlesinger N, Schlesinger M, Seshan SV (2003). Seasonal Variations of Lupus Nephritis [Abstract]. (Supplement), #PUB554.
    120. Schlesinger N (2000). Fibromyalgia in sickle cell patients: Clues to understanding the pathogenesis of fibromyalgia [Abstract]. 48(9 Suppl), S706.
    121. Schlesinger N, Johanson WG, Jr, Jyoti Rao, Jayanti Rao, Schumacher HR Jr (1999). A survey of current evaluation and treatment of gout [Abstract]. 42(9 Suppl), S536.
    122. Schlesinger N, Lardizabal A, Jayanti Rao, Jyoti Rao, Kapila R, McDonald R (1999). Tuberculosis of the spine: Experience in an inner city hospital [Abstract]. 42(9 Suppl), S1611.
    123. Schlesinger N, Farrukh K, Barrett K, Hoffman BI, Schumacher HR Jr (1997). A survey of corticosteroid use in rheumatoid arthritis [Abstract]. 40(9 Suppl), S194.
    124. Schlesinger N, Sieck M, Clayburne G, Schumacher HR Jr (1997). Does acute synovitis (pseudogout) occur in patients with chronic pyrophosphate arthropathy or are these separate syndromes? [Abstract]. 40(9 Suppl), S49.
    125. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Persian Gulf war myalgia syndrome [Abstract]. 39(9 Suppl), S47.
    126. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Acute gouty arthritis is seasonal [Abstract]. 39(9 Suppl), S85.
    127. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Serum uric acid during bouts of acute gouty arthritis [Abstract]. 39(9 Suppl), S84.
    128. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Local ice therapy during bouts of acute gouty arthritis [Abstract]. 39(9 Suppl), S84.
    129. Saaibi DL, Clayburne G, Schlesinger N, Schumacher HR Jr, Gowin KM (1996). Seasonal variation in serum uric acid levels [Abstract]. 39(9 Suppl), S85.
    130. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr (1996). Allopurinol may have protective effect against acute gout attacks independently from its hypouricemic action [Abstract]. 39(9 Suppl), S85.

    Other

    1. Schlesinger N (2002). Readers want to know. Should one ice a gouty knee? (16, p. 16).

    Video/Film/CD/Web/Podcast

    1. Wick G, Anaya JM, Andrarde, Schlesinger N, Touinou P, et al (2019). Allowing an open discussion of the side effects of vaccines [e-letter] [Web]. Science. Available: https://science.sciencemag.org/content/366/6466/675/tab-e-letters.
    2. Schlesinger N (2018). Gout linked to increased risk for erectile dysfunction [Web]. Healio News. Available: https://www.healio.com/rheumatology/gout/news/online/ %7B3f32ad1e-b43a-4cd6-b5f1-e8423a85ec0c%7D/gout-linked-to-increased-risk-for- erectile-dysfunction.
    3. Schlesinger N (2012). Gout Diagnosis: 4 Common Misconceptions [Web]. www.consultantlive.com: Consultant Live. Available: http://www.consultantlive.com/musculoskeletal-disorders/display/article/10162/2099778.
    4. Schlesinger N (2009). Managing Gout - From Acute Relief to Long-term Control [Web]. Medscape CME. Available: http://cme.medscape.com/viewarticle/701583.
  • News & Podcasts